Almirall Licenses IL-21 Antibody from Novo Nordisk
Novo Nordisk will receive upfront, milestone and royalty payments for developing and marketing the dermatology asset. Almirall has signed an exclusive licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s… Read More




